Connect with us

Stock News

Cassava Sciences settles SEC charges of ‘misleading’ Alzheimer’s trial claims

Published

2 months ago

on


Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two former executives for “misleading claims” about an Alzheimer’s clinical trial.

Related Topics:
Continue Reading

Stock News

Here are 4 biotech stocks that could get a boost from a more open FDA regulatory climate

Published

54 minutes ago

on

November 18, 2024

By


Biotech-stock investing has one tough test for success — and it’s about to get easier

Continue Reading

Stock News

Corporate bond spreads hit a record low last week — and may be an early sign of a bubble

Published

2 hours ago

on

November 18, 2024

By


Investment-grade and high-yield spreads tightened to record levels over Treasurys.

Continue Reading

Stock News

Caregivers’ retirement security — often jeopardized by time away from work — could get a boost from these proposals

Published

3 hours ago

on

November 18, 2024

By


“Family members often make tremendous sacrifices to leave the workforce and care for their aging relatives, and as a result, they miss out on key years of saving for their own golden years.”

Continue Reading

Trending